Mallinckrodt plc appointed Lisa French as Executive Vice President and Chief Commercial Officer, effective October 1, 2022. Ms. French brings more than 30 years of commercial biopharmaceutical experience and will oversee the development and execution of Mallinckrodt's commercialization strategy. Ms. French will serve on the Executive Committee and succeeds Hugh O'Neill, who departed Mallinckrodt as of September 16, 2022.

Ms. French most recently built and led the U.S. Women's Health Commercial team for Organon & Co. following its spin-off from Merck. Previously, she held numerous leadership positions at Merck, where she ultimately led all aspects of a multibillion-dollar brand, executed commercial innovation initiatives and oversaw multiple sales teams.